Whalesbook
India's pharmaceutical industry is a major economic force, ranking third globally in volume and eleventh by value. The domestic market, worth nearly $60 billion and home to over 3,000 companies and 10,500 manufacturing units, is projected to reach $130 billion by 2030. This strong growth, fueled by rising healthcare needs, impressive exports, and ongoing innovation, has significantly increased investor interest in pharma mutual funds.
These specialized funds invest in pharmaceutical, healthcare, and related companies, aiming to capture sector-specific growth. Here, we examine five top-performing pharma mutual funds in India based on their 3-year and 5-year returns.
India's Pharma Sector Growth
The Indian pharma market is on a strong growth path. Projections indicate it will more than double its current value within a decade, driven by growing domestic healthcare needs and global demand for affordable generics and active pharmaceutical ingredients (APIs). This outlook makes pharma mutual funds appealing for investors wanting exposure to this dynamic industry.
Top Pharma Fund Performance
Looking at the top funds reveals diverse strategies and results:
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund (AUM Rs 62.93 billion) delivered a 5-year CAGR of 16.10%, slightly beating its benchmark, the BSE Healthcare TRI (15.08%). Its portfolio focuses heavily on healthcare (90.79%), with top holdings like Sun Pharmaceutical Industries Ltd. and Cipla Ltd.
SBI Healthcare Opportunities Fund (AUM Rs 40.63 billion) recorded a 5-year CAGR of 17.55%, also ahead of the BSE Healthcare TRI (15.09%). The fund uses a bottom-up stock-picking strategy across market caps, with substantial exposure to large and mid-cap healthcare stocks.
UTI Healthcare Fund (AUM Rs 11.43 billion) leans towards mid-cap and small-cap companies. While its 3-year return (24.93%) trailed its benchmark slightly, its 1-year performance of 8.33% beat the BSE Healthcare TRI's 6.27%.
Tata India Pharma & Healthcare Fund (AUM Rs 12.29 billion) showed weaker recent performance. Over three years, it returned 7.62%, trailing its benchmark's 11.53%. The fund blends large-cap (35.95%) and small-cap (39.74%) stocks.
DSP Healthcare Fund (AUM Rs 31.42 billion) invests in both Indian and global healthcare. Its 5-year CAGR of 13.64% was below the benchmark's 14.33%, suggesting a need for careful evaluation of its varied strategy.
When considering these funds, investors should look beyond headline returns. Important metrics like standard deviation, Sharpe ratio, and expense ratios offer key insights into risk-adjusted performance and costs. While the sector's growth forecast is strong, individual fund results will depend on stock selection, market cap focus, and overall economic conditions.